Gateway Investment Advisers LLC Sells 26,306 Shares of IQVIA Holdings Inc. $IQV

Key Points

• Gateway Investment Advisers LLC cut its stake in IQVIA by 42.1% in Q4, selling 26,306 shares and leaving it with 36,167 shares worth about $8.15 million.
• IQVIA beat quarterly expectations (EPS $2.90 vs. $2.83 est.; revenue $4.15B, +8.4% YoY) and set FY 2026 guidance of 12.65–12.95 EPS.
• The board authorized a $2.00 billion share buyback (about 6.8% of outstanding shares), and analysts have an average "Buy" rating with a consensus price target near $225.69.

Gateway Investment Advisers LLC decreased its position in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 42.1% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 36,167 shares of the medical research company's stock after selling 26,306 shares during the quarter. Gateway Investment Advisers LLC's holdings in IQVIA were worth $8,152,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Ameliora Wealth Management Ltd. bought a new position in IQVIA during the 4th quarter worth approximately $25,000. Physician Wealth Advisors Inc. boosted its stake in IQVIA by 1,340.0% during the 3rd quarter. Physician Wealth Advisors Inc. now owns 144 shares of the medical research company's stock worth $27,000 after acquiring an additional 134 shares during the last quarter. Westside Investment Management Inc. boosted its stake in IQVIA by 219.6% during the 3rd quarter. Westside Investment Management Inc. now owns 147 shares of the medical research company's stock worth $30,000 after acquiring an additional 101 shares during the last quarter. Measured Wealth Private Client Group LLC bought a new position in IQVIA during the 3rd quarter worth approximately $30,000. Finally, Activest Wealth Management boosted its stake in IQVIA by 590.0% during the 4th quarter. Activest Wealth Management now owns 138 shares of the medical research company's stock worth $31,000 after acquiring an additional 118 shares during the last quarter. Institutional investors own 89.62% of the company's stock.

IQVIA Stock Up 1.4%

IQVIA stock opened at $178.95 on Friday. The stock has a market capitalization of $29.87 billion, a PE ratio of 22.17, a price-to-earnings-growth ratio of 1.75 and a beta of 1.18. IQVIA Holdings Inc. has a twelve month low of $134.65 and a twelve month high of $247.04. The company has a quick ratio of 0.75, a current ratio of 0.75 and a debt-to-equity ratio of 2.20. The company has a 50 day moving average of $170.14 and a 200-day moving average of $200.95.

IQVIA (NYSE:IQV - Get Free Report) last released its quarterly earnings results on Tuesday, May 5th. The medical research company reported $2.90 earnings per share for the quarter, beating the consensus estimate of $2.83 by $0.07. The company had revenue of $4.15 billion during the quarter, compared to analysts' expectations of $4.10 billion. IQVIA had a net margin of 8.33% and a return on equity of 30.50%. The business's quarterly revenue was up 8.4% compared to the same quarter last year. During the same quarter in the prior year, the company earned $2.70 earnings per share. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. On average, equities research analysts anticipate that IQVIA Holdings Inc. will post 11.5 EPS for the current fiscal year.

IQVIA announced that its board has initiated a share buyback plan on Thursday, May 7th that allows the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization allows the medical research company to purchase up to 6.8% of its stock through open market purchases. Stock repurchase plans are typically a sign that the company's leadership believes its shares are undervalued.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on IQV shares. Weiss Ratings lowered IQVIA from a "hold (c)" rating to a "hold (c-)" rating in a research report on Monday. Evercore reaffirmed an "outperform" rating and set a $185.00 price target on shares of IQVIA in a research report on Wednesday, April 8th. Barclays raised shares of IQVIA from an "equal weight" rating to an "overweight" rating and set a $210.00 price target on the stock in a research note on Friday, March 6th. Mizuho set a $215.00 price target on shares of IQVIA in a report on Monday, February 23rd. Finally, Royal Bank Of Canada initiated coverage on shares of IQVIA in a report on Tuesday, March 3rd. They issued an "outperform" rating and a $221.00 price target for the company. Two analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat.com, IQVIA has an average rating of "Buy" and a consensus price target of $225.69.

IQVIA Company Profile

IQVIA NYSE: IQV is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA's principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.

Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IQVIA Holdings Inc. (NYSE:IQV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.